Key result
Mepolizumab is linked to acute myocarditis and elevated Th1/Th17 cytokines in EGPA.
Why the study?
The efficacy of mepolizumab 100 mg/month on major clinical features of eosinophilic granulomatosis with polyangiitis, including cardiac involvement, is uncertain.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bello et al. (2021) conducted a case report in Eosinophilic granulomatosis with polyangiitis (EGPA) (n=1). Mepolizumab was evaluated on Development of acute myocarditis and changes in peripheral T lymphocyte cytokine production. Mepolizumab therapy in a patient with EGPA was associated with the development of acute myocarditis and a rise in Th1/Th17-related cytokines, suggesting incomplete protection from vasculitic events.
Synapse has enriched 10 related papers. Consider them for comparative context: